Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging
Background 18 F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of 18 F-fluciclovine in breast cancer and assessed differences in t...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2022-03, Vol.126 (4), p.598-605 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 605 |
|---|---|
| container_issue | 4 |
| container_start_page | 598 |
| container_title | British journal of cancer |
| container_volume | 126 |
| creator | Scott, N. P. Teoh, E. J. Flight, H. Jones, B. E. Niederer, J. Mustata, L. MacLean, G. M. Roy, P. G. Remoundos, D. D. Snell, C. Liu, C. Gleeson, F. V. Harris, A. L. Lord, S. R. McGowan, D. R. |
| description | Background
18
F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of
18
F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades.
Methods
Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of
18
F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters.
Results
A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation.
Conclusions
18
F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake.
Clinical Trial Registration
NCT03036943. |
| doi_str_mv | 10.1038/s41416-021-01623-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8854436</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629521787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-16bd6155ed31f0ff4c152f452253095aad73ab297bccacad7525ff3f3180c8f43</originalsourceid><addsrcrecordid>eNp9kUtLJDEUhcPgMLbO_AFXAdfR3DyqUhtBGl8g6KJnHVKppDptd6pNqoT-92amG8WNq8vlnvPdAwehM6AXQLm6zAIEVIQyIBQqxgn_gWYgOSOgWH2EZpTSmtCG0WN0kvOqrA1V9S90zEXdSEGbGTLzpUnGji6FHGKPQd0Sv55ssOvhLUSHp-1oXhwOEbfJmTxia6J1CY_LNEz9ssyiyQ4PHne7aDbB4uebxeV8gcPG9AX5G_30Zp3dn8M8RX9vbxbze_L4dPcwv34klisYCVRtV4GUruPgqffCgmReSMYkp400pqu5aVlTt9YaWzbJpPfcc1DUKi_4Kbrac7dTu3GddXFMZq23qeRIOz2YoL9eYljqfnjTSkkheFUA5wdAGl4nl0e9GqYUS2bNKtZIBrWqi4rtVTYNOSfnPz4A1f9q0ftadKlF_69F82Lie1Mu4ti79In-xvUO2BaPbA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629521787</pqid></control><display><type>article</type><title>Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging</title><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Scott, N. P. ; Teoh, E. J. ; Flight, H. ; Jones, B. E. ; Niederer, J. ; Mustata, L. ; MacLean, G. M. ; Roy, P. G. ; Remoundos, D. D. ; Snell, C. ; Liu, C. ; Gleeson, F. V. ; Harris, A. L. ; Lord, S. R. ; McGowan, D. R.</creator><creatorcontrib>Scott, N. P. ; Teoh, E. J. ; Flight, H. ; Jones, B. E. ; Niederer, J. ; Mustata, L. ; MacLean, G. M. ; Roy, P. G. ; Remoundos, D. D. ; Snell, C. ; Liu, C. ; Gleeson, F. V. ; Harris, A. L. ; Lord, S. R. ; McGowan, D. R.</creatorcontrib><description>Background
18
F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of
18
F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades.
Methods
Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of
18
F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters.
Results
A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation.
Conclusions
18
F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake.
Clinical Trial Registration
NCT03036943.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-021-01623-3</identifier><identifier>PMID: 34795409</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308/575 ; 692/4028/67/1347 ; 692/4028/67/2321 ; Amino acids ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Cancer Research ; Computed tomography ; Drug Resistance ; Epidemiology ; Molecular Medicine ; Oncology ; Positron emission tomography ; Prostate cancer ; Tomography ; Tumors</subject><ispartof>British journal of cancer, 2022-03, Vol.126 (4), p.598-605</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-16bd6155ed31f0ff4c152f452253095aad73ab297bccacad7525ff3f3180c8f43</citedby><cites>FETCH-LOGICAL-c381t-16bd6155ed31f0ff4c152f452253095aad73ab297bccacad7525ff3f3180c8f43</cites><orcidid>0000-0003-1376-8409 ; 0000-0001-7946-5609 ; 0000-0002-6880-5687 ; 0000-0001-7847-3041</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854436/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854436/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,41467,42536,51297,53769,53771</link.rule.ids></links><search><creatorcontrib>Scott, N. P.</creatorcontrib><creatorcontrib>Teoh, E. J.</creatorcontrib><creatorcontrib>Flight, H.</creatorcontrib><creatorcontrib>Jones, B. E.</creatorcontrib><creatorcontrib>Niederer, J.</creatorcontrib><creatorcontrib>Mustata, L.</creatorcontrib><creatorcontrib>MacLean, G. M.</creatorcontrib><creatorcontrib>Roy, P. G.</creatorcontrib><creatorcontrib>Remoundos, D. D.</creatorcontrib><creatorcontrib>Snell, C.</creatorcontrib><creatorcontrib>Liu, C.</creatorcontrib><creatorcontrib>Gleeson, F. V.</creatorcontrib><creatorcontrib>Harris, A. L.</creatorcontrib><creatorcontrib>Lord, S. R.</creatorcontrib><creatorcontrib>McGowan, D. R.</creatorcontrib><title>Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Background
18
F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of
18
F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades.
Methods
Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of
18
F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters.
Results
A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation.
Conclusions
18
F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake.
Clinical Trial Registration
NCT03036943.</description><subject>692/308/575</subject><subject>692/4028/67/1347</subject><subject>692/4028/67/2321</subject><subject>Amino acids</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Cancer Research</subject><subject>Computed tomography</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Positron emission tomography</subject><subject>Prostate cancer</subject><subject>Tomography</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtLJDEUhcPgMLbO_AFXAdfR3DyqUhtBGl8g6KJnHVKppDptd6pNqoT-92amG8WNq8vlnvPdAwehM6AXQLm6zAIEVIQyIBQqxgn_gWYgOSOgWH2EZpTSmtCG0WN0kvOqrA1V9S90zEXdSEGbGTLzpUnGji6FHGKPQd0Sv55ssOvhLUSHp-1oXhwOEbfJmTxia6J1CY_LNEz9ssyiyQ4PHne7aDbB4uebxeV8gcPG9AX5G_30Zp3dn8M8RX9vbxbze_L4dPcwv34klisYCVRtV4GUruPgqffCgmReSMYkp400pqu5aVlTt9YaWzbJpPfcc1DUKi_4Kbrac7dTu3GddXFMZq23qeRIOz2YoL9eYljqfnjTSkkheFUA5wdAGl4nl0e9GqYUS2bNKtZIBrWqi4rtVTYNOSfnPz4A1f9q0ftadKlF_69F82Lie1Mu4ti79In-xvUO2BaPbA</recordid><startdate>20220309</startdate><enddate>20220309</enddate><creator>Scott, N. P.</creator><creator>Teoh, E. J.</creator><creator>Flight, H.</creator><creator>Jones, B. E.</creator><creator>Niederer, J.</creator><creator>Mustata, L.</creator><creator>MacLean, G. M.</creator><creator>Roy, P. G.</creator><creator>Remoundos, D. D.</creator><creator>Snell, C.</creator><creator>Liu, C.</creator><creator>Gleeson, F. V.</creator><creator>Harris, A. L.</creator><creator>Lord, S. R.</creator><creator>McGowan, D. R.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1376-8409</orcidid><orcidid>https://orcid.org/0000-0001-7946-5609</orcidid><orcidid>https://orcid.org/0000-0002-6880-5687</orcidid><orcidid>https://orcid.org/0000-0001-7847-3041</orcidid></search><sort><creationdate>20220309</creationdate><title>Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging</title><author>Scott, N. P. ; Teoh, E. J. ; Flight, H. ; Jones, B. E. ; Niederer, J. ; Mustata, L. ; MacLean, G. M. ; Roy, P. G. ; Remoundos, D. D. ; Snell, C. ; Liu, C. ; Gleeson, F. V. ; Harris, A. L. ; Lord, S. R. ; McGowan, D. R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-16bd6155ed31f0ff4c152f452253095aad73ab297bccacad7525ff3f3180c8f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>692/308/575</topic><topic>692/4028/67/1347</topic><topic>692/4028/67/2321</topic><topic>Amino acids</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Cancer Research</topic><topic>Computed tomography</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Positron emission tomography</topic><topic>Prostate cancer</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, N. P.</creatorcontrib><creatorcontrib>Teoh, E. J.</creatorcontrib><creatorcontrib>Flight, H.</creatorcontrib><creatorcontrib>Jones, B. E.</creatorcontrib><creatorcontrib>Niederer, J.</creatorcontrib><creatorcontrib>Mustata, L.</creatorcontrib><creatorcontrib>MacLean, G. M.</creatorcontrib><creatorcontrib>Roy, P. G.</creatorcontrib><creatorcontrib>Remoundos, D. D.</creatorcontrib><creatorcontrib>Snell, C.</creatorcontrib><creatorcontrib>Liu, C.</creatorcontrib><creatorcontrib>Gleeson, F. V.</creatorcontrib><creatorcontrib>Harris, A. L.</creatorcontrib><creatorcontrib>Lord, S. R.</creatorcontrib><creatorcontrib>McGowan, D. R.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, N. P.</au><au>Teoh, E. J.</au><au>Flight, H.</au><au>Jones, B. E.</au><au>Niederer, J.</au><au>Mustata, L.</au><au>MacLean, G. M.</au><au>Roy, P. G.</au><au>Remoundos, D. D.</au><au>Snell, C.</au><au>Liu, C.</au><au>Gleeson, F. V.</au><au>Harris, A. L.</au><au>Lord, S. R.</au><au>McGowan, D. R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><date>2022-03-09</date><risdate>2022</risdate><volume>126</volume><issue>4</issue><spage>598</spage><epage>605</epage><pages>598-605</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
18
F-fluciclovine is a synthetic amino acid positron emission tomography (PET) radiotracer that is approved for use in prostate cancer. In this clinical study, we characterised the kinetic model best describing the uptake of
18
F-fluciclovine in breast cancer and assessed differences in tracer kinetics and static parameters for different breast cancer receptor subtypes and tumour grades.
Methods
Thirty-nine patients with pathologically proven breast cancer underwent 20-min dynamic PET/computed tomography imaging following the administration of
18
F-fluciclovine. Uptake into primary breast tumours was evaluated using one- and two-tissue reversible compartmental kinetic models and static parameters.
Results
A reversible one-tissue compartment model was shown to best describe tracer uptake in breast cancer. No significant differences were seen in kinetic or static parameters for different tumour receptor subtypes or grades. Kinetic and static parameters showed a good correlation.
Conclusions
18
F-fluciclovine has potential in the imaging of primary breast cancer, but kinetic analysis may not have additional value over static measures of tracer uptake.
Clinical Trial Registration
NCT03036943.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34795409</pmid><doi>10.1038/s41416-021-01623-3</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1376-8409</orcidid><orcidid>https://orcid.org/0000-0001-7946-5609</orcidid><orcidid>https://orcid.org/0000-0002-6880-5687</orcidid><orcidid>https://orcid.org/0000-0001-7847-3041</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2022-03, Vol.126 (4), p.598-605 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8854436 |
| source | Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 692/308/575 692/4028/67/1347 692/4028/67/2321 Amino acids Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Computed tomography Drug Resistance Epidemiology Molecular Medicine Oncology Positron emission tomography Prostate cancer Tomography Tumors |
| title | Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterising%2018F-fluciclovine%20uptake%20in%20breast%20cancer%20through%20the%20use%20of%20dynamic%20PET/CT%20imaging&rft.jtitle=British%20journal%20of%20cancer&rft.au=Scott,%20N.%20P.&rft.date=2022-03-09&rft.volume=126&rft.issue=4&rft.spage=598&rft.epage=605&rft.pages=598-605&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-021-01623-3&rft_dat=%3Cproquest_pubme%3E2629521787%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2629521787&rft_id=info:pmid/34795409&rfr_iscdi=true |